Decreased plasma levels of omeprazole after coadministration with magnesium-aluminium hydroxide dry suspension granules

Yakugaku Zasshi

Volumn 119, Issue 3, 1999, Pages 221-228

  Iwao, Kazunari ^a   Saitoh, Hiroshi ^a   Takeda, Kiyotaka ^b   Azuumi, Yoshiteru ^b   Takada, Masahiko ^a  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b Sapporo Higashi Tokushukai Hospital   (Japan)

Author keywords

Drug interaction; Healthy male subject; Maalox granule; Maalox suspension; Omeprazole; Plasma level

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; LEVOFLOXACIN; OMEPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DETERMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG STABILITY; ENTERIC COATED TABLET; HUMAN; MALE; METABOLIC INHIBITION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PH;

EID: 0032974232     PISSN: 00316903     EISSN: None     Source Type: Journal    
DOI: 10.1248/yakushi1947.119.3_221     Document Type: Article

References (11)

1. Gugler R., Allgayer H., Clin. Pharmacokinet., 18, 210-219 (1990).
2. Neuvonen P. J., Kivistö K. T., Clin. Pharmacokinet., 27, 120-128 (1994).
3. Tuynman H. A. R. E., Festen H. P. M., Röhss K., Meuwissen S. G. M., Br. J. Clin. Pharmacol., 24, 833-835 (1987).
4. Howden C. W., Reid J. L., Br. J. Clin. Pharmacol., 25, 779-781 (1988).
5. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., J. Pharmacobio-Dyn., 4, 879-885 (1981).
6. Gillum J. G., Israel D. S., Polk R. E., Clin. Pharmacokinet., 25, 450-482 (1993).